Genmab A/S (GMAB) Expected to Announce Earnings on Wednesday

Genmab A/S (NASDAQ:GMAB) is projected to post its quarterly earnings results on Wednesday, February 12th. Analysts expect Genmab A/S to post earnings of $0.28 per share and revenue of $884.02 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $18.69 on Tuesday. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The stock has a market capitalization of $12.37 billion, a PE ratio of 18.15, a P/E/G ratio of 0.54 and a beta of 0.96. The company has a fifty day moving average of $20.84 and a two-hundred day moving average of $23.37.

Analyst Ratings Changes

Several equities research analysts have issued reports on GMAB shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.